Enterprise Unit
Licensing & Partnering Opportunities
Currently there are a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators.
Platforms/Software Applications
View our Portfolio of Licensing and Partnering Opportunities
Therapeutics
Aurora Kinase Inhibitors
Cancer Research Technology collaboration and licensing opportunity.
Principal Scientists: Dr Spiros Linardopoulos and Professor Julian Blagg
Novel inhibitors of Aurora Kinase enzymes, both pan specific and Aurora A specific. Proof of concept demonstrated in vivo.
For more information contact Angela Kukula or download the PDF flyer
GDEPT - Gene Directed Enzyme Prodrug Therapy
Cancer Research Technology collaboration and licensing opportunity.
Principal Scientist: Professor Caroline Springer
Gene directed enzyme prodrug therapy. CPG2 enzyme. Exclusive rights in the GDEPT field to develop the prodrug ZD2767P. Wide range of additional prodrugs. Rights to novel vectors and molecular imaging probes. Proof of concept demonstrated in vivo. First product in pre-clinical development. Phase I due to start 2011.
For more information contact Sue Sherry or download the PDF flyer
B-RAF Inhibitors
Wellcome Trust licensing opportunity.
Principal Scientists: Professor Richard Marais and Professor Caroline Springer
Novel inhibitors of enzyme B-RAF. Four chemical series, three pre-clinical candidates. Proof of concept demonstrated in vivo. Compounds orally active in melanoma and colorectal xenograft models. Compounds demonstrate a range of selectivity profiles.
For further information contact Angela Kukula or download the PDF flyer
CHK1 Cell Cycle Checkpoint Kinase Inhibitors
Cancer Research Technology collaboration and licensing opportunity
Principal Scientists: Dr Ian Collins and Professor Paul Workman
Over half of all cancers are functionally deficient for the p53 pathway, which often makes them resistant to genotoxic cancer treatments. Chk1 inhibitors are designed to selectively sensitise p53 defective cells to such therapies. We have progressed potent specific non-toxic, orally bioavalible Chk1 inhibitors from several novel chemical series into late-lead optimisation. They show in vivo biomarker modulation and potentation of DNA damaging agents.
For more information contact Angela Kukula or download the PDF flyer
CHK2 Cell Cycle Checkpoint Kinase Inhibitors
Cancer Research Technology collaboration and licensing opportunity
Principal Scientists: Dr Michelle Garrett and Professor Paul Workman
The cell cycle checkpoint kinase CHK2 is a key multi-functional player in the induction of cell cycle arrest and apoptosis caused by DNA damage. We believe that modulation of it could prove to be an effective anti-cancer strategy. So far we have identified and progressed two promising series of novel CHK2 inhibitors into lead optimisation.
For more information contact Angela Kukula or download the PDF flyer
Chaperonin CCT Inhibitors
ICR collaboration and licensing opportunity.
Principal Scientists: Professor Keith Willison and Professor Paul Workman
CCT folds the key oncology drug targets actin and tubulin and its inhibition offers the opportunity of a novel approach to generating improved anti-mitotics. Assays to enable the isolation of this megadalton multisubunit complex and screening for inhibitors have been developed and a drug discovery programme initiated.
For more information contact Angela Kukula
Targets
ETV1 Fusion Gene in Prostate Cancer
ICR collaboration and licensing opportunity.
Principal Scientists: Professor Colin Cooper
A new ETV1 fusion partner has been identified which has shown a correlation between ETV1 rearrangement and Gleason score in prostate cancer.
For more information contact Jonathan Beech
HDAC9, A Novel Histone Deacetylase
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Arthur Zelent
Characterisation of a novel HDAC associated with cancer. Potential drug target and diagnostic marker.
For further information contact Paul Carnochan or download the PDF flyer
Glypican-5, A Novel Cancer Target
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Janet Shipley
GPC5 has been identified as a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma. This target is amenable to antibody mediated therapies. It also has potential as a biomarker.
For further information contact Jonathan Beech.
Diagnostic Biomarkers
Monoclonal Antibodies against Cerb-B2
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Steve Hobbs and Dr Suzanne Eccles
A panel of rat anti Cerb-B2 antibodies has been developed and is now available for diagnostic and therapeutic applications. Extensive pre-clinical evaluation has been completed.
For further information contact Jonathan Beech or download the PDF flyer
Monoclonal Antibodies against EGFR
ICR licensing opportunity.
Principal Scientist: Dr Suzanne Eccles
A set of rat monoclonal anti EGFR antibodies has been developed and are available for diagnostic and therapeutic applications. Extensive preclinical characterisation completed. One antibody has completed Phase 1B Clinical trials.
For further information contact Jonathan Beech or download the PDF flyer
Anti-KSR Monoclonal Antibody
Cancer Research Technology licensing opportunity.
Principal Scientist: Professor Richard Marais
Clone name: MINT/1/4 Host species: rat Ig isotype: IgG2a Immunogen: Full length mouse KSR-GST fusion Protein Antibody available for licensing.
For more information contact Enterprise Unit
Prognostic Test for Multiple Myeloma
ICR collaboration and licensing opportunity.
Principal Scientist: Professor Gareth Morgan
Relative expression from three gene pairs has been identified as a test for identifying ~20% of multiple myeloma patients who will not respond to conventional chemotherapy treatments and for whom alternative regimens should be explored.
For more information contact Angela Kukula or download the PDF flyer
Devices
Device for Tissue Processing
ICR licensing opportunity.
Principal Scientists: Dr Sameer Jhavar and Dr Stefan Reinsberg
Laboratory tool for rapid and accurate slicing of fresh tissue samples, providing for co-alignment with tissue imaging.
For more information contact Jennifer Hodgson or download the PDF flyer
Variable Aperture Collimator (VApC) for Radiotherapy Delivery
ICR & Cancer Research Centre Heidelberg commercial opportunity: Licence and collaboration.
Principal Scientist: Professor Steve Webb
Apparatus and method for conformal delivery of radiotherapy treatment.
For further information contact Jonathan Beech or download the PDF flyer
High Resolution Gamma Ray Imaging Device
Gamma Technologies Ltd collaboration and licensing opportunity.
Principal Scientist: Professor Bob Ott
Novel gamma ray imaging device with the potential to dramatically enhance the resolution and sensitivity of nuclear medicine imaging.
For more information contact Paul Carnochan
PETRRA, Novel PET Camera
PETTRA Ltd collaboration and licensing opportunity.
Principal Scientists: Professor Bob Ott
Novel large area PET camera that provides functional and economic advantages over existing systems.
For more information contact Paul Carnochan
Platforms / Software Applications
4D Orthogonal Display Tool
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Michael Khazen and Professor Martin Leach
Software for rapid identification of tissue movement during MR imaging Evaluation ongoing
For further information Paul Carnochan or download the PDF Flyer
Dosimetry Software Package
ICR collaboration and licensing opportunity.
Principle Scientist: Dr Glenn Flux
Dosimetry software package for application in targeted radionuclide therapy.
For more information contact Jonathan Beech or download the PDF flyer
MRI Distortion Correction
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Stefan Reinsberg and Professor Martin Leach
Algorithms for evaluation and correction of geometric distortion in MR images, for applications including radiotherapy treatment planning.
For more information contact Jennifer Hodgson or download to PDF flyer
3D Kinetic Volume Rendering Tool
ICR collaboration and licensing opportunity.
Principle Scientist: Dr Michael Khazen
Software to combine 3D volume rendering of anatomical structures and colour encoded kinetic information.
For more information contact Paul Carnochan
Fat Suppression Tool for MRI
ICR licensing opportunity.
Principal Scientists: Dr Michael Khazen and Professor Martin Leach
A novel method for visualisation and suppression of fat signals associated with MR imaging.
For further information contact Paul Carnochan or download the PDF flyer
Autobeam - Radiation Treatment Planning Software
ICR collaboration and licensing opportunity.
Principal Scientist: Dr James Bedford
Software application for optimisation of advanced conformal and intensity-modulated radiotherapy treatments.
For more information contact Paul Carnochan
View our Portfolio of Licensing and Partnering Opportunities
